<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="epub">2296-2360</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31157196</article-id>
<article-id pub-id-type="pmc">6529843</article-id>
<article-id pub-id-type="doi">10.3389/fped.2019.00199</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pediatrics</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Alagille Syndrome: A Novel Mutation in <italic>JAG1</italic> Gene</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fischetto</surname>
<given-names>Rita</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/725975/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Palmieri</surname>
<given-names>Viviana V.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/665638/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tripaldi</surname>
<given-names>Maria E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaeta</surname>
<given-names>Alberto</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Michelucci</surname>
<given-names>Angela</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/657176/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Delvecchio</surname>
<given-names>Maurizio</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/500927/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Francavilla</surname>
<given-names>Ruggiero</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/139370/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giordano</surname>
<given-names>Paola</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Clinical Genetics Unit, Department of Paediatric Medicine, Giovanni XXIII Children's Hospital</institution>, <addr-line>Bari</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Pediatric Section, Department of Biomedicine and Human Oncology, University A. Moro</institution>, <addr-line>Bari</addr-line>, <country>Italy</country></aff>
<aff id="aff3"><sup>3</sup><institution>PediatricRadiology Unit, Giovanni XXIII Children's Hospital</institution>, <addr-line>Bari</addr-line>, <country>Italy</country></aff>
<aff id="aff4"><sup>4</sup><institution>Laboratory of Molecular Genetics, University Hospital of Pisa</institution>, <addr-line>Pisa</addr-line>, <country>Italy</country></aff>
<aff id="aff5"><sup>5</sup><institution>Pediatrics Unit, “Madonna delle Grazie” Hospital</institution>, <addr-line>Matera</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Merlin Gene Butler, University of Kansas Medical Center, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Zohreh Talebizadeh, Children's Mercy Hospital, United States; Douglas Bittel, Kansas City University, United States</p>
</fn>
<corresp id="c001">*Correspondence: Viviana V. Palmieri <email>viviana_palmieri@libero.it</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Genetic Disorders, a section of the journal Frontiers in Pediatrics</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>7</volume>
<elocation-id>199</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Fischetto, Palmieri, Tripaldi, Gaeta, Michelucci, Delvecchio, Francavilla and Giordano.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Fischetto, Palmieri, Tripaldi, Gaeta, Michelucci, Delvecchio, Francavilla and Giordano</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Alagille syndrome is an autosomal dominant multisystem disorder with variable phenotypic penetrance, caused by heterozygous mutations in <italic>JAG1</italic> or <italic>NOTCH2</italic>, encoding for the components of the Notch signaling pathway. In this paper, we described a novel mutation not yet reported in literature. This 3-years old male child was referred to our Clinical Genetics Unit because of delayed psychomotor development, systolic murmur, dysmorphic facial features, and hypertransaminasemia. The novel <italic>JAG1</italic> heterozygous <italic>c.2026delT</italic> variant in exon 16 was found. <italic>JAG1</italic> mutations are classified as protein truncating and non-protein truncating, without any genotype-phenotype correlation. The detected mutation determines a stop codon (p.Cys676AlafsTer67) in the gene sequence, encoding a truncated protein. Our report broadens the spectrum of <italic>JAG1</italic> gene mutations.</p>
</abstract>
<kwd-group>
<kwd>Alagille syndrome</kwd>
<kwd>
<italic>JAG1</italic>
</kwd>
<kwd>stop codon mutation</kwd>
<kwd>Next Generation Sequencing</kwd>
<kwd>hypertransaminasemia</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="3"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="26"></ref-count>
<page-count count="5"></page-count>
<word-count count="3170"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Background</title>
<p>Alagille syndrome (ALGS; OMIM 118450) is an autosomal dominant multisystem disorder with variable phenotypic penetrance first described in 1969 by Daniel Alagille (<xref ref-type="bibr" rid="B1">1</xref>). The incidence rate is 1:70,000–100,000 live births (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Molecular diagnosis has increased the number of cases detected and the true incidence is probably close to 1 in 30,000 (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Although clinical features may differ significantly, the diagnosis of ALGS is mainly based on clinical findings (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Initial diagnosis is based on the presence of intrahepatic bile duct paucity and at least of 3 other clinical features: chronic cholestasis, cardiac disease (pulmonary stenosis), ocular abnormalities (posterior embryotoxon), skeletal abnormalities (butterfly-like vertebrae), and peculiar facial features (broad forehead, deep-set eyes, bulbous nose, and small pointed mandible) (<xref ref-type="bibr" rid="B7">7</xref>–<xref ref-type="bibr" rid="B9">9</xref>). Patients have a high prevalence of renal and vascular disease as well (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<p>ALGS is caused by mutations in genes that impair Notch signaling, a highly conserved pathway that is fundamental to the transcription of genes for cell fate and differentiation of multiple organ systems (<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B14">14</xref>). Almost all cases of ALGS are caused by mutations in the <italic>JAG1</italic> gene (20p12.2), which consists of 26 exons, while a small rate of patients has a heterozygous mutation in the Notch receptor<italic>, NOTCH2</italic> gene (1p13) (<xref ref-type="bibr" rid="B15">15</xref>–<xref ref-type="bibr" rid="B18">18</xref>). Although mutations causing ALGS have now been identified, diagnostic challenges remain because there are not genotype–phenotype correlations (<xref ref-type="bibr" rid="B19">19</xref>). Albeit several genotype-phenotype correlation studies have been performed, they have not shown a link between mutation type and clinical manifestation or severity, leading to the hypothesis that a second gene could work to modify the effects of a <italic>JAG1</italic> or <italic>NOTCH2</italic> mutation (<xref ref-type="bibr" rid="B1">1</xref>). The diagnosis is based on clinical features. Liver biopsy typically shows paucity of the intrahepatic bile ducts, but it is no longer considered mandatory to make a diagnosis of ALGS, and the presence of cholestasis is acceptable to fulfill this criterion. Confirmatory diagnosis is based on gene sequencing. However, about 4% of patients with clinical diagnosis of ALGS may not show any genetic variant, suggesting that further genetic mechanisms are still to be elucidated (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<p>In this paper, we describe a patient carrying a novel mutation not yet reported in literature. Signed informed consent has been acquired from the patient's parents for the publication of this case report and any potentially identifying information was removed.</p>
</sec>
<sec id="s2">
<title>Case Report</title>
<p>The patient is a Caucasian 3-years old male child, late-preterm born (36 weeks) from vaginal delivery, after a pregnancy complicated by placental detachment. Birth weight was 2,490 g (26° centile). He was the first child of an unrelated couple. Family history was negative for cardiac or hepatic disorders. The main stages of psychomotor development were delayed (sitting position at 8 months with hypotonia; walking at 18 months; speaking at 3 years). At 20 months of age a systolic murmur was found at the cardiac auscultation and heart ultrasound was performed, showing a mild stenosis of the pulmonary branches. Screening for metabolic diseases was negative, except for the finding of hypertransaminasemia. Because of dysmorphic facial features, delayed neurological development and elevated liver enzymes, a genetic condition was suspected and the patient was referred to the Clinical Genetics Unit of the Giovanni XXIII Children's Hospital in Bari.</p>
<p>At referral, height, weight and head circumference were normal (&gt;50° centile). He featured prominent frontal bossing, saddle nose with a bulbous tip, 2/VI systolic cardiac murmur, severe psychomotor retardation suggesting an autistic phenotype. His stools were hypocholic with remains of undigested food. Fundus oculi and brain resonance were normal. Karyotype and FRAXA analysis resulted negative. After patient's parents signed the informed consent, gene sequencing of <italic>JAG1</italic> (NM_000214) was performed by Next Generation Sequencing. Target enrichment was done by TruSeq custom amplicon (Illumina, San Diego, CA, United States) according to the manufacturer's instructions. Template library was prepared and was sequenced using MiseqIllumina platform (Illumina, San Diego, CA, United States). Annotation and filtering of variants were performed with Illumina Variant Studio version 2.0, following recommended settings. To evaluate the completeness of the method for the screening of the targeted gene, the sequencing coverage of each amplicon was analyzed in detail using Integrative Genome Viewer version 2.3 (Broad Institute, Cambridge, MA). Variants and region with a depth coverage below 30x were confirmed by Sanger sequencing. The heterozygous sequence variant c.2026delT; p.Cys676AlafsTer67 in exon 16 was identified and confirmed using Sanger sequencing (<xref ref-type="fig" rid="F1">Figure 1</xref>), also because the coverage in exon 16 was very low (&lt;30 x). Primers sequences for PCR amplification of the exon 16 were designed using Primer3 software: Forward primer CCTGTCGTGAATGGTCCTG, Reverse primer CCAGGCCCAGAGAAATATCA. The variant was absent in both parents, arisen as a <italic>de novo</italic> variant, which determines the formation of a stop codon. Variant was checked for previously reported causative mutations in published works and mutation databases: Human Gene Mutation Database (HGMD) and Leiden Open Variation Database (LOVD) and it has never been described before. Moreover, variant was searched indbSNP, 1,000 Genomes and ExACdatbases, to exclude common single nucleotide polymorphism.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>The figure displays the heterozygous sequence variant c.2026delT (p.Cys676AlafsTer67) in exon 16 identified and confirmed by Sanger sequencing in the upper part and the wild type sequence at the bottom.</p>
</caption>
<graphic xlink:href="fped-07-00199-g0001"></graphic>
</fig>
<p>The child started symptomatic therapy with ursodeoxycholic acid and multidisciplinary follow-up, in particular rehabilitative psychomotor follow-up.</p>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>Alagille syndrome is a highly variable, autosomal dominant disorder, which involves multiple organ systems. <xref ref-type="table" rid="T1">Table 1</xref> shows a summary of the clinical characteristics and its frequency in patients with ALGS. Its management requires a multidisciplinary team, including mainly specialists in medical genetics, gastroenterology, hepatology, nutrition, cardiology, ophthalmology, and many others (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). The main clinical and pathological features are chronic cholestasis, characteristic facial features, cardiac defect, minor abnormalities of vertebral segmentation, ophthalmologic abnormalities, and dysplastic kidneys (<xref ref-type="bibr" rid="B20">20</xref>). The liver disease typically causes severe debilitating pruritus and disfiguring xanthomas, which require treatment with ursodeoxycholic acid and other medications such as cholestyramine, rifampin, and naltrexone (<xref ref-type="bibr" rid="B22">22</xref>). Infants and children with ALGS are often diagnosed based on their clinical features: chronic cholestasis is the most common presenting attribute of patients, but dysmorphic facial features are considered one of the best ways to diagnose ALGS (<xref ref-type="bibr" rid="B5">5</xref>). The differential diagnosis included Progressive Familiar Cholestasis (PFIC), childhood primary sclerosing cholangitis, congenital hepatic fibrosis, childhood autoimmune hepatitis, childhood primary biliary cirrhosis, alpha-1 antitripsin deficiency, cystic fibrosis and other diseases in which paucity of bile ducts occurs (<xref ref-type="bibr" rid="B3">3</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>A summary of the clinical features and the frequency reported among individuals with ALGS.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Common system involved</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Overall frequency</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Frequency of Finding in <italic>JAG1</italic>+ ALGS</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>This case</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liver: Paucity of biliary duct, conjugated hyperbilirubinemia and liver failure</td>
<td align="center" colspan="1" rowspan="1" valign="top">Up to 100%</td>
<td align="center" colspan="1" rowspan="1" valign="top">100%</td>
<td align="center" colspan="1" rowspan="1" valign="top">√</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Heart: Structural changes, pulmonary stenosis, and tetralogy of Fallot</td>
<td align="center" colspan="1" rowspan="1" valign="top">90–97%; 60–67%, and 7–16%</td>
<td align="center" colspan="1" rowspan="1" valign="top">100%</td>
<td align="center" colspan="1" rowspan="1" valign="top">√</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Facial features: Prominent forehead, deep-set eyes with moderate hypertelorism, pointed chin, and saddle or straight nose with a bulbous tip</td>
<td align="center" colspan="1" rowspan="1" valign="top">20–97%</td>
<td align="center" colspan="1" rowspan="1" valign="top">97%</td>
<td align="center" colspan="1" rowspan="1" valign="top">√</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Eye: Posterior embryotoxon</td>
<td align="center" colspan="1" rowspan="1" valign="top">78–89%</td>
<td align="center" colspan="1" rowspan="1" valign="top">75%</td>
<td align="center" colspan="1" rowspan="1" valign="top">X</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bones: Vertebral anomalies (butterfly vertebra)</td>
<td align="center" colspan="1" rowspan="1" valign="top">33–93%</td>
<td align="center" colspan="1" rowspan="1" valign="top">64%</td>
<td align="center" colspan="1" rowspan="1" valign="top">Not available</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kidney: Ureteropelvic obstruction and renal tubular acidosis</td>
<td align="center" colspan="1" rowspan="1" valign="top">39%</td>
<td align="center" colspan="1" rowspan="1" valign="top">40%</td>
<td align="center" colspan="1" rowspan="1" valign="top">X</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Adapted from Saleh et al. (<xref ref-type="bibr" rid="B20">20</xref>). √: present; X: not present</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>ALGS is caused by heterozygous mutations in 1 of 2 genes that are fundamental components of the Notch signaling pathway, JAGGED1 and Notch 2. Mutations in <italic>JAG1</italic> gene were first identified more than 20 years ago, and above 500 mutations have been reported (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). The spectrum of <italic>JAG1</italic> mutations includes more frequently protein-truncating mutations (75%), and non-protein truncating mutations (25%) (<xref ref-type="table" rid="T2">Tables 2A,B</xref>) (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Sequencing all exons and the immediately adjacent intronic regions to identify splice site mutations allows to identify the majority of <italic>JAG1</italic> and <italic>NOTCH2</italic> mutations. Because mutations in <italic>JAG1</italic> are predominant, sequencing of this gene occurs first followed by deletion or duplication analysis via multiplex ligation-dependent probe amplification, chromosomal microarray, or fluorescence <italic>in situ</italic> hybridization. Sequencing of <italic>JAG1</italic> identifies approximately 85% of ALGS mutations, and deletion/duplication analysis yields an additional approximately 9% of molecular diagnoses. In the absence of an identified mutation in <italic>JAG1</italic>, sequencing of <italic>NOTCH2</italic> identifies another 2 to 3% of mutations in ALGS. Up to date large deletion or duplication mutations in <italic>NOTCH2</italic> have not been reported. A causative mutation for the remaining 2 to 4% of clinically diagnosed ALGS patients has not been identified yet, and the application of various next-generation sequencing techniques could help identify a molecular origin in this population (<xref ref-type="bibr" rid="B1">1</xref>). Unfortunately no genotype-phenotype correlation exists between clinical manifestations and the specific <italic>JAG1</italic> pathogenic variant or the location of the mutation within gene (<xref ref-type="bibr" rid="B19">19</xref>). Although genetics of ALGS is well-defined, there is a very variable expressivity of the disease. Individuals with the same mutations, including patients belonging to the same family, show discordance in the phenotype (<xref ref-type="bibr" rid="B1">1</xref>). In support of this concept, the genotype-phenotype correlation studies did not identify a link between the mutation type and clinical manifestation or severity (<xref ref-type="bibr" rid="B18">18</xref>). In view of the absence of an identified environmental factor that influences the severity of the disease or presentation, scientists hypothesized that a second gene could work modifying the effects of a <italic>JAG1</italic> or <italic>NOTCH2</italic> mutation to worsen or improve the disease features. Several studies have identified putative genetic modifiers to help explain the variable expressivity of this disease (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2A</label>
<caption>
<p>Type and frequency of <italic>JAG1</italic> mutations found in ALGS.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Mutation type</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Reported (n)</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Frequency (%)</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Protein truncating</td>
<td align="left" colspan="1" rowspan="1" valign="top">Small deletions</td>
<td align="center" colspan="1" rowspan="1" valign="top">150</td>
<td align="center" colspan="1" rowspan="1" valign="top">28.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Small duplications/insertions</td>
<td align="center" colspan="1" rowspan="1" valign="top">102</td>
<td align="center" colspan="1" rowspan="1" valign="top">19.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Non sense</td>
<td align="center" colspan="1" rowspan="1" valign="top">85</td>
<td align="center" colspan="1" rowspan="1" valign="top">16.1</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Gross deletions</td>
<td align="center" colspan="1" rowspan="1" valign="top">47</td>
<td align="center" colspan="1" rowspan="1" valign="top">8.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Indels</td>
<td align="center" colspan="1" rowspan="1" valign="top">12</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Non-protein truncating</td>
<td align="left" colspan="1" rowspan="1" valign="top">Missense</td>
<td align="center" colspan="1" rowspan="1" valign="top">81</td>
<td align="center" colspan="1" rowspan="1" valign="top">15.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Splice site</td>
<td align="center" colspan="1" rowspan="1" valign="top">47</td>
<td align="center" colspan="1" rowspan="1" valign="top">8.9</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Gross duplications/insertions</td>
<td align="center" colspan="1" rowspan="1" valign="top">2</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Translocations</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.2</td>
</tr>
<tr style="border-top: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">Total</td>
<td colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1" valign="top">527</td>
<td align="center" colspan="1" rowspan="1" valign="top">100</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Adapted from Mitchell et al. (<xref ref-type="bibr" rid="B1">1</xref>)</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table 2B</label>
<caption>
<p>Exons more frequently involved per genetic mutation (Results for variants in the <italic>JAG1</italic> gene reported in the ClinVar database).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Exons more frequentlyinvolved per genetic mutation</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Deletions: Exon 2,7,16,17,23,25</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Duplications: Exon 3,8,11,13,17,18,23,24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Insertions: Exon 8, 23</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Stop codon mutations: Exon 3,4,6,20,21,23,24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Missense: Exon 1,2,4,5,9,20</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Splicing mutations: Exon 16</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The patient described in this paper was referred to our Unit because of psycho-motor delay, autistic pattern, facial dysmorphic features, and hypertransaminasemia. Thus, at referral beside the typical liver involvement which is the main feature of ALGS, the clinical features of our patient were facial features, heart disease, and severe neurological involvement; the less frequent clinical features in ALGS were not present in our case (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p>The <italic>JAG1</italic> gene sequencing showed the novel<italic>c.2026delT</italic> variant in exon 16, which determines a stop codon (p.Cys676AlafsTer67) in the gene sequence. As a result, this mutation produces a truncated protein. Although exon 16 has already been described as a site of disease-causing mutations, this variant has not been reported yet in literature. Further studies could clarify the effect of this mutation, but the stop codon causes the premature truncation of the amino acids sequence. In the same position, it was previously reported the <italic>de novo</italic> c.2026T&gt;G variant leading to the p.C676G missense mutation which was disease-causing according to the Mutation Tester and probably damaging according to the PolyPhen-2 (<xref ref-type="bibr" rid="B25">25</xref>). The mutation was found in a male with 4 clinical features (cholestasis, cardiac murmur, skeletal abnormalities, characteristic face). The majority of point and frameshift mutations could be detected by sequencing 11 exons (exons 3, 5, 6, 11, 14, 16, 18, 21, and 23–25). It has been reported that exon 16 is involved mostly by deletions and splicing mutations, due to a single nucleotide substitution (such c.2071T&gt;A, c.2078G&gt;A, and c.2091G&gt;A) or small duplications (c.2070_2073dupCTGT) (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>). In this paper we describe a patient with Alagille syndrome carrying a frameshift mutation in the exon 16 of <italic>JAG1</italic> gene. This exon is frequently involved by disease-causing mutations in Alagille syndrome.</p>
</sec>
<sec id="s4">
<title>Concluding Remarks</title>
<p>Our report broadens the spectrum of mutations in the <italic>JAG1</italic> gene. Broadening the mutations spectrum may help genetists to better identify etiological mutations leading to ALGS and overall it could provide further insights to identify the hotspots exons where mutations happen more frequently.</p>
</sec>
<sec id="s5">
<title>Ethics Statement</title>
<p>Signed informed consent has been acquired from the patient's parents for the publication of this case report and any potentially identifying information was removed. Gene sequencing was performed after informed consent was signed by the patient's parents.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>RiF and RuF were in charge of clinical follow-up of the patient. VP and MT drafted the paper. AG is the radiologist who performed the imaging. AM is the biologist who ran the gene sequencing. MD and PG reviewed the paper and gave substantial contribution to data interpretation.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>E</given-names></name><name><surname>Gilbert</surname><given-names>M</given-names></name><name><surname>Loomes</surname><given-names>KM</given-names></name></person-group>. <article-title>Alagille syndrome</article-title>. <source/>Clin Liver Dis. (<year>2018</year>) <volume>22</volume>:<fpage>625</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.cld.2018.06.001</pub-id><pub-id pub-id-type="pmid">30266153</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vajro</surname><given-names>P</given-names></name><name><surname>Ferrante</surname><given-names>L</given-names></name><name><surname>Paolella</surname><given-names>G</given-names></name></person-group>. <article-title>Alagille syndrome: an overview</article-title>. <source/>Clin Res Hepatol Gastroenterol. (<year>2012</year>) <volume>36</volume>:<fpage>275</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinre.2012.03.019</pub-id><pub-id pub-id-type="pmid">22521120</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnpenny</surname><given-names>PD</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name></person-group>. <article-title>Alagille syndrome: pathogenesis, diagnosis and management</article-title>. <source/>Eur J Hum Genet. (<year>2012</year>) <volume>20</volume>:<fpage>251</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2011.181</pub-id><pub-id pub-id-type="pmid">21934706</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>BM</given-names></name><name><surname>Bason</surname><given-names>L</given-names></name><name><surname>Piccoli</surname><given-names>DA</given-names></name><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name></person-group>. <article-title>Consequences of JAG1 mutations</article-title>. <source/>J Med Genet. (<year>2003</year>) <volume>40</volume>:<fpage>891</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.40.12.891</pub-id><pub-id pub-id-type="pmid">14684686</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jesina</surname><given-names>D</given-names></name></person-group>. <article-title>Alagille syndrome: an overview</article-title>. <source/>Neonatal Netw. (<year>2017</year>). <volume>36</volume>:<fpage>343</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1891/0730-0832.36.6.343</pub-id><pub-id pub-id-type="pmid">29185945</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>P</given-names></name><name><surname>Knisely</surname><given-names>A</given-names></name><name><surname>Portmann</surname><given-names>B</given-names></name><name><surname>Qureshi</surname><given-names>SA</given-names></name><name><surname>Aclimandos</surname><given-names>WA</given-names></name><name><surname>Karani</surname><given-names>JB</given-names></name><etal></etal></person-group>. <article-title>Diagnosis of Alagille syndrome−25 years of experience at King's college hospital</article-title>. <source/>J Pediatr Gastroenterol Nutr. (<year>2011</year>) <volume>52</volume>:<fpage>84</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/MPG.0b013e3181f1572d</pub-id><pub-id pub-id-type="pmid">21119543</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes-de la Rosa</surname><given-names>ADP</given-names></name><name><surname>Varela-Fascinetto</surname><given-names>G</given-names></name><name><surname>García-Delgado</surname><given-names>C</given-names></name><name><surname>Vázquez-Martínez</surname><given-names>ER</given-names></name><name><surname>Valencia-Mayoral</surname><given-names>P</given-names></name><name><surname>Cerbón</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>A Novel c.91dupG JAG1 gene mutation is associated with early onset and severe alagille syndrome</article-title>. <source/>Case Rep Genet. (<year>2018</year>). <volume>2018</volume>:<fpage>369413</fpage>. <pub-id pub-id-type="doi">10.1155/2018/1369413</pub-id><pub-id pub-id-type="pmid">30046498</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JM</given-names></name><name><surname>Jafar-Nejad</surname><given-names>H</given-names></name></person-group>. <article-title>A new model of alagille syndrome with broad phenotypic representation</article-title>. <source/>Gastroenterology. (<year>2018</year>) <volume>154</volume>:<fpage>803</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2018.02.007</pub-id><pub-id pub-id-type="pmid">29425927</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>KJ</given-names></name><name><surname>Yoon</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>GB</given-names></name><name><surname>Kwon</surname><given-names>BS</given-names></name><name><surname>Go</surname><given-names>JM</given-names></name><name><surname>Moon</surname><given-names>JS</given-names></name><etal></etal></person-group>. <article-title>Alagille syndrome and a JAG1mutation: 41 cases of experience at a single center</article-title>. <source/>Korean J Pediatr. (<year>2015</year>) <volume>58</volume>:<fpage>392</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3345/kjp.2015.58.10.392</pub-id><pub-id pub-id-type="pmid">26576184</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>MA</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name></person-group>. <article-title>Alagille syndrome: Genetics and Functional Models</article-title>. <source/>Curr Pathobiol Rep. (<year>2017</year>) <volume>5</volume>:<fpage>233</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s40139-017-0144-8</pub-id><pub-id pub-id-type="pmid">29270332</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penton</surname><given-names>AL</given-names></name><name><surname>Leonard</surname><given-names>LD</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name></person-group>. <article-title>Notch signaling in human development and disease</article-title>. <source/>Semin Cell Dev Biol. (<year>2012</year>) <volume>23</volume>:<fpage>450</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2012.01.010</pub-id><pub-id pub-id-type="pmid">22306179</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>SJ</given-names></name></person-group>
<article-title>Notch signaling in context</article-title>. <source/>Nat Rev Mol Cell Biol. (<year>2016</year>) <volume>17</volume>:<fpage>722</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2016.94</pub-id><pub-id pub-id-type="pmid">27507209</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Genin</surname><given-names>A</given-names></name><name><surname>Banta</surname><given-names>AB</given-names></name><name><surname>Collins</surname><given-names>CC</given-names></name><etal></etal></person-group>. <article-title>Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1</article-title>. <source/>Nat Genet. (<year>1997</year>) <volume>16</volume>:<fpage>243</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/ng0797-243</pub-id><pub-id pub-id-type="pmid">9207788</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guegan</surname><given-names>K</given-names></name><name><surname>Stals</surname><given-names>K</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Turnpenny</surname><given-names>P</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name></person-group>. <article-title>JAG1 mutations are found in approximately one third of patients presenting with only one or two clinical features of Alagille syndrome</article-title>. <source/>Clin Genetics. (<year>2012</year>) <volume>82</volume>:<fpage>33</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01749.x</pub-id><pub-id pub-id-type="pmid">21752016</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spinner</surname><given-names>NB</given-names></name><name><surname>Leonard</surname><given-names>LD</given-names></name><name><surname>Krantz</surname><given-names>LD</given-names></name></person-group>
<source/>Alagille Syndrome. <publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>Gene Reviews</publisher-name> (<year>2013</year>).</mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Piccoli</surname><given-names>DA</given-names></name><name><surname>Spinner</surname><given-names>NB</given-names></name></person-group>. <article-title>Alagille syndrome</article-title>. <source/>J Med Genet. (<year>1997</year>) <volume>34</volume>:<fpage>152</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.34.2.152</pub-id><pub-id pub-id-type="pmid">9039994</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDaniell</surname><given-names>R</given-names></name><name><surname>Warthen</surname><given-names>DM</given-names></name><name><surname>Sanchez-Lara</surname><given-names>PA</given-names></name><name><surname>Pai</surname><given-names>A</given-names></name><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Piccoli</surname><given-names>DA</given-names></name><etal></etal></person-group>. <article-title>NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the Notch signaling pathway</article-title>. <source/>Am J Hum Genet. (<year>2006</year>) <volume>79</volume>:<fpage>169</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1086/505332</pub-id><pub-id pub-id-type="pmid">16773578</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinner</surname><given-names>NB</given-names></name><name><surname>Colliton</surname><given-names>RP</given-names></name><name><surname>Crosnier</surname><given-names>C</given-names></name><name><surname>Krantz</surname><given-names>ID</given-names></name><name><surname>Hadchouel</surname><given-names>M</given-names></name><name><surname>Meunier-Rotival</surname><given-names>M</given-names></name></person-group>. <article-title>Jagged1 mutations in Alagille syndrome</article-title>. <source/>Hum Mutat. (<year>2001</year>) <volume>17</volume>:<fpage>18</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/1098-1004(2001)17:1&lt;18::AID-HUMU3&gt;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">11139239</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>BM</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Houwen</surname><given-names>R</given-names></name><name><surname>Todorova</surname><given-names>L</given-names></name><name><surname>Kerkar</surname><given-names>N</given-names></name></person-group>. <article-title>Systematic Review: The Epidemiology, Natural History, and Burden of Alagille Syndrome</article-title>. <source/>J Pediatr Gastroenterol Nutr. (<year>2018</year>) <volume>67</volume>:<fpage>148</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1097/MPG.0000000000001958</pub-id><pub-id pub-id-type="pmid">29543694</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Kamath</surname><given-names>BM</given-names></name><name><surname>Chitayat</surname><given-names>D</given-names></name></person-group>. <article-title>Alagille syndrome: clinical perspectives</article-title>. <source/>Appl Clin Genetics. (<year>2016</year>) <volume>9</volume>:<fpage>75</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.2147/TACG.S86420</pub-id><pub-id pub-id-type="pmid">27418850</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HP</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Choe</surname><given-names>YH</given-names></name></person-group>. <article-title>Outcome of alagille syndrome patients who had previously received kasai operation during infancy: a single center study</article-title>. <source/>Ped Gastroenter Hepat Nutr. (<year>2015</year>) <volume>18</volume>:<fpage>175</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5223/pghn.2015.18.3.175</pub-id><pub-id pub-id-type="pmid">26473137</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouzaki</surname><given-names>M</given-names></name><name><surname>Bass</surname><given-names>LM</given-names></name><name><surname>Sokol</surname><given-names>RJ</given-names></name><name><surname>Piccoli</surname><given-names>DA</given-names></name><name><surname>Quammie</surname><given-names>C</given-names></name><name><surname>Loomes</surname><given-names>KM</given-names></name><etal></etal></person-group>. <article-title>Early life predictive markers of liver disease outcome in an International, Multicentre Cohort of children with Alagille syndrome</article-title>. <source/>Liver Int. (<year>2016</year>) <volume>36</volume>:<fpage>755</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1111/liv.12920</pub-id><pub-id pub-id-type="pmid">26201540</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togawa</surname><given-names>T</given-names></name><name><surname>Sugiura</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Endo</surname><given-names>T</given-names></name><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next-generation sequencing</article-title>. <source/>J Pediatr. (<year>2016</year>) <volume>171</volume>:<fpage>171</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2016.01.006</pub-id><pub-id pub-id-type="pmid">26858187</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Mort</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>EV</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Hayden</surname><given-names>M</given-names></name><name><surname>Heywood</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies</article-title>. <source/>Hum Genet. (<year>2017</year>) <volume>136</volume>:<fpage>665</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-017-1779-6</pub-id><pub-id pub-id-type="pmid">28349240</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>JAG1 mutation spectrum and origin in chinese children with clinical features of alagille syndrome</article-title>. <source/>PLoS ONE. (<year>2015</year>) <volume>10</volume>:<fpage>e0130355</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0130355</pub-id><pub-id pub-id-type="pmid">26076142</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warthen</surname><given-names>DM</given-names></name><name><surname>Moore</surname><given-names>EC</given-names></name><name><surname>Kamath</surname><given-names>BM</given-names></name><name><surname>Morrissette</surname><given-names>JJ</given-names></name><name><surname>Sanchez-Lara</surname><given-names>PA</given-names></name><name><surname>Piccoli</surname><given-names>DA</given-names></name><etal></etal></person-group>. <article-title>Mutations in alagille syndrome: increasing the mutation detection rate</article-title>. <source/>Hum. Mut. (<year>2006</year>) <volume>27</volume>:<fpage>436</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/humu.20310</pub-id><pub-id pub-id-type="pmid">16575836</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>